COVID-19 and the kidney: what we think we know so far and what we don't

Samira S Farouk, Enrico Fiaccadori, Paolo Cravedi, Kirk N Campbell, Samira S Farouk, Enrico Fiaccadori, Paolo Cravedi, Kirk N Campbell

Abstract

The novel coronavirus disease infection (COVID-19) outbreak that was declared a global pandemic in March 2020 had led to an internationally variable but concerning incidence of COVID-associated acute kidney injury (AKI), with prevalence reported as high as 46% in large cohorts of hospitalized patients. Variability in AKI may be explained by differences in traditional risk factors for AKI, heterogeneity among patient cohorts, and differences in racial and ethnic groups. Further, AKI requiring kidney replacement therapies (KRT) has been associated with increased mortality. Proposed mechanisms of kidney injury include direct viral-induced tubular or glomerular injury, sepsis-associated AKI, and thrombotic disease. Kidney pathology include acute tubular injury, glomerular fibrin thrombi, pigmented tubular casts, and collapsing focal segmental glomerulosclerosis. "Viral-like" particles have been observed in renal samples at electron microscopy and viral RNA has been identified in both glomerular and tubular compartments of kidney specimens, but the link between viral presence and injury remain unclear. Though the link between AKI and poor outcomes is clear, prevalence and outcomes of COVID-19 in patients with chronic kidney disease and end stage kidney disease has not yet been reported. In patients on immunosuppression like those with kidney transplants or glomerular disease, COVID-19 has presented a management dilemma. Herein, we review the existing literature on kidney disease in COVID-19 and discuss what remains to be learned.

Keywords: Acute kidney injury; COVID-19; Kidney transplant; SARS-CoV2.

Conflict of interest statement

This manuscript has not been published previously, in whole or part. The authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Incidence of acute kidney injury (AKI) reported in China (black bars), Ireland, United Kingdom, Wales, and United States. Three studies included only patients requiring intensive care [1, 12, 13] while others included hospitalized patients

References

    1. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–838. doi: 10.1016/j.kint.2020.03.005.
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30079-5.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Wang L, Li X, Chen H, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020 doi: 10.1159/000507471.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.
    1. Diao B, Wang C, Wang R, et al. human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv. 2020 doi: 10.1101/2020.03.04.20031120.
    1. Xiao G, Hu H, Wu F, et al. Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. medRxiv. 2020 doi: 10.1101/2020.04.06.20055194.
    1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Cao M, Zhang D, Wang Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv. 2020 doi: 10.1101/2020.03.04.20030395.
    1. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–374. doi: 10.1007/s11427-020-1643-8.
    1. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 doi: 10.1093/cid/ciaa199.
    1. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–1614. doi: 10.1001/jama.2020.4326.
    1. ICNARC—Intensive Care National Audit & Research Centre. . Accessed 20 May 2020
    1. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 doi: 10.1016/j.kint.2020.05.006.
    1. Mohamed MM, Lukitsch I, Torres-Ortiz AE, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney. 2020 doi: 10.34067/KID.0002652020.
    1. Pei G, Zhang Z, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020 doi: 10.1681/ASN.2020030276.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Malberti F, Pecchini P, Marchi G, Foramitti M. When a nephrology ward becomes a COVID-19 ward: the Cremona experience. J Nephrol. 2020 doi: 10.1007/s40620-020-00743-y.
    1. Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hospitalized patients with COVID-19. medRxiv. 2020 doi: 10.1101/2020.05.04.20090944.
    1. Levey AS, Eckardt K-U, Dorman NM, et al. Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2020;97:1117–1129. doi: 10.1016/j.kint.2020.02.010.
    1. Acute Kidney Injury. In: NephJC. . Accessed 4 May 2020
    1. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020 doi: 10.1056/NEJMc2011117.
    1. Calomeni E, Satoskar A, Ayoub I, et al. Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney Int. 2020 doi: 10.1016/j.kint.2020.05.003.
    1. Miller SE, Brealey JK. Visualization of putative coronavirus in kidney. Kidney Int. 2020 doi: 10.1016/j.kint.2020.05.004.
    1. Aiamkitsumrit B, Sullivan NT, Nonnemacher MR, et al. Human immunodeficiency virus type 1 cellular entry and exit in the T lymphocytic and monocytic compartments: mechanisms and target opportunities during viral disease. Adv Virus Res. 2015;93:257–311. doi: 10.1016/bs.aivir.2015.04.001.
    1. Pacciarini F, Ghezzi S, Canducci F, et al. Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. J Virol. 2008;82:5137–5144. doi: 10.1128/JVI.00096-08.
    1. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 doi: 10.1016/j.kint.2020.04.003.
    1. Lerolle N, Nochy D, Guérot E, et al. Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med. 2010;36:471–478. doi: 10.1007/s00134-009-1723-x.
    1. Aslan A, van den Heuvel MC, Stegeman CA, et al. Kidney histopathology in lethal human sepsis. Crit Care. 2018;22:359. doi: 10.1186/s13054-018-2287-3.
    1. Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19) J Pathol. 2020 doi: 10.1002/path.5471.
    1. Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-COV2 interaction with renin angiotensin system. J Am Coll Cardiol. 2020 doi: 10.1016/j.jacc.2020.04.028.
    1. Kissling S, Rotman S, Gerber C, et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020 doi: 10.1016/j.kint.2020.04.006.
    1. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.
    1. Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020 doi: 10.1056/NEJMc2011400.
    1. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost JTH. 2020 doi: 10.1111/jth.14849.
    1. Rossi GM, Delsante M, Pilato FP, et al. Kidney biopsy findings in a critically ill COVID-19 patient with dialysis-dependent acute kidney injury: a case against “SARS-CoV-2 nephropathy”. Kidney Int Rep. 2020 doi: 10.1016/j.ekir.2020.05.005.
    1. Li Z, Wu M, Volunteers A-2019-nCoV et al. Caution on kidney dysfunctions of COVID-19 patients. medRxiv. 2020 doi: 10.1101/2020.02.08.20021212.
    1. Larsen CP, Bourne TD, Wilson JD, et al. Collapsing glomerulopathy in a patient with coronavirus disease 2019 (COVID-19) Kidney Int Rep. 2020 doi: 10.1016/j.ekir.2020.04.002.
    1. Peleg Y, Kudose S, D’Agati V, et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep. 2020 doi: 10.1016/j.ekir.2020.04.017.
    1. Bromfield M, McQuillan R, John R, Avila-Casado C. The significance of tubuloreticular inclusions as a marker of systemic stimulation by interferons in a case of focal and segmental glomerulosclerosis associated with cytomegalovirus (CMV) infection. Clin Kidney J. 2014;7:174–178. doi: 10.1093/ckj/sft156.
    1. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol CJASN. 2008;3:1526–1533. doi: 10.2215/CJN.00950208.
    1. Yamada T, Mikami T, Chopra N, et al. Patients with chronic kidney disease have a poorer prognosis of coronavirus disease 2019 (COVID-19): an experience in New York City. Int Urol Nephrol. 2020 doi: 10.1007/s11255-020-02494-y.
    1. Alberici F, Delbarba E, Manenti C, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020 doi: 10.1016/j.kint.2020.04.030.
    1. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97:1083–1088. doi: 10.1016/j.kint.2020.04.002.
    1. Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol. 2020;31:1145–1146. doi: 10.1681/ASN.2020030348.
    1. Fishman JA, Grossi PA. Novel coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. Am J Transplant. 2020;20:1765–1767. doi: 10.1111/ajt.15890.
    1. Bomback AS, Canetta PA, Ahn W, et al. How COVID-19 has changed the management of glomerular diseases. Clin J Am Soc Nephrol. 2020 doi: 10.2215/CJN.04530420.
    1. Billah M, Santeusanio A, Delaney V, et al. A catabolic state in a kidney transplant recipient with COVID-19. Transpl Int Off J Eur Soc Organ Transpl. 2020 doi: 10.1111/tri.13635.
    1. Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020 doi: 10.1681/ASN.2020040419.
    1. Oberg AL, Kennedy RB, Li P, et al. Systems biology approaches to new vaccine development. Curr Opin Immunol. 2011;23:436–443. doi: 10.1016/j.coi.2011.04.005.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する